After gaining regulatory clearance both sides of the pond, Orthopaedic and Biotech company Biomet Orthopedics, LLC, is now reporting first clinical use of its OsseoTi Porous Technology for total hip arthroplasty.
Through the use of a proprietary manufacturing process, OsseoTi Porous Technology uses human CT data, in combination with 3D printing technology, to build a structure that directly mimics the architecture of human cancellous bone. This process generates a single porous architecture that allows creation of complex shapes, while maintaining the consistent porosity and strength necessary to facilitate bone and tissue ingrowth and implant stability. When applied to the G7 Acetabular System, this provides surgeons the benefits of highly porous technology in combination with a sizing rationale designed for hip stability.
CE mark and FDA clearance were achieved in November and December 2014, respectively, with first clinical use also performed in Europe in December 2014. The G7 OsseoTi shell is used in conjunction with Biomet’s G7 Acetabular System, a multi-bearing acetabular platform designed to deliver simplicity, efficiency and performance for primary and revision hip arthroplasty.
Source: Business Wire